Evidence map›Paper›PMID 42394706›Full record

ArticleFrontiers in oncology2026

Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review.

Daxia Cai, Jun Li, Qiyi Chen, Xingdong Cai, Feng Tian, Yanyan Zhu, Jingjing Cao, Jianhui Huang, Xiu Lan, Zhifeng Tian and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daxia Cai *Cancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
Jun Li *Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Qiyi ChenDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Xingdong CaiDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Feng TianDepartment of General Surgery, Lishui People's Hospital, the Six Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
Yanyan ZhuDepartment of Pharmacy, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
Jingjing CaoPathology department, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
Jianhui HuangCancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
Xiu LanCancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
Zhifeng TianCancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
Jianfei TuCancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
Yonghui WangCancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is frequently underdiagnosed or misdiagnosed due to its rarity and complex histological features. To date, no universally recommended treatment regimens have been established for this rare subtype, and clinical management is currently extrapolated primarily from standard non-small cell lung cancer (NSCLC) protocols. Herein, we report a case of PSC initially diagnosed as multiple primary lung cancer, including adenosquamous carcinoma and adenocarcinoma (pT1N0M0, IA stage, EGFR Exon-21 L858R mutation, below the detection limit) and adenocarcinoma (pT2aN0M0, stage IB, EGFR Exon-21 L858R mutation). Despite radical surgical resection followed by targeted therapy with afatinib (30 mg orally once daily), the disease recurred. Repeat biopsy confirmed the diagnosis of PSC secondary to histological transformation. The patient achieved a durable complete response (CR) to combined immunochemotherapy. We further review the existing literature on EGFR-TKI-associated histological transformation in lung cancer, to provide guidance for the clinical management of this challenging clinical scenario.

Indexed as

EGFR-TKIshistological transformationnon-small cell lung cancer (NSCLC)pulmonary sarcomatoid carcinomaresistance mechanism

Identifiers

PMID42394706
PMCPMC13322830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.